November 10, 2016
1 min read
Save
This article is more than 5 years old. Information may no longer be current.
Ocular Therapeutix reports lower net loss in third quarter
You've successfully added to your alerts. You will receive an email when new content is published.
Click Here to Manage Email Alerts
Click Here to Manage Email Alerts
We were unable to process your request. Please try again later. If you continue to have this issue please contact customerservice@slackinc.com.
Ocular Therapeutix reported a net loss of $9.6 million, or $0.39 per share, in the third quarter compared with a net loss of $11.5 million, or $0.47 per share, in the third quarter of 2015, according to a company press release.
Total costs and operating expenses were $9.7 million compared with $11.6 million in the third quarter of 2015, while research and development costs decreased from $8.3 million to $5.7 million. The decrease was attributed to lower clinical trial costs.
Revenue totaled $477,000 compared with $429,000 in the third quarter of 2015.